Profiel
Georges Rawadi served as the Chief Executive Officer and Executive Director at Celyad Oncology SA in 2023 and as the Chief Executive Officer and Director at YSOPIA Biosciences SA from 2018 to 2021.
Prior to that, he was the Vice President of Business Development at Celyad Oncology SA from 2014 to 2018 and held the same position at Cellectis SA. Rawadi holds a doctorate from Université Pierre et Marie Curie and a graduate degree from ESSEC Business School.
Eerdere bekende functies van Georges Rawadi
| Bedrijven | Functie | Einde |
|---|---|---|
| CELYAD ONCOLOGY SA | Algemeen Directeur | 01-12-2023 |
YSOPIA Biosciences SA
 YSOPIA Biosciences SA BiotechnologyHealth Technology LNC Therapeutics SA operates as a research and development company that designs and develops medical food formulas. It's develop therapeutic solutions for metabolic and cardiometabolic disorders. The firm also designs and develops formulas for obesity and pre-diabetes sickness. Its products include Stablor, Bariamed, and Fertimed. It encompass serious game, patient community, and support tools: BariaSpoon and BariaFork. The company was founded by Jérôme Théron and Claude Vincent on October 29, 2010 and is headquartered in Bordeaux, France. | Algemeen Directeur | 01-09-2021 |
| CELYAD ONCOLOGY SA | Corporate Officer/Principal | 23-03-2018 |
| CELLECTIS S.A. | Corporate Officer/Principal | - |
Opleiding van Georges Rawadi
| ESSEC Business School | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| CELYAD ONCOLOGY SA | Health Technology |
| CELLECTIS S.A. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| Université Pierre et Marie Curie | Consumer Services |
YSOPIA Biosciences SA
YSOPIA Biosciences SA BiotechnologyHealth Technology LNC Therapeutics SA operates as a research and development company that designs and develops medical food formulas. It's develop therapeutic solutions for metabolic and cardiometabolic disorders. The firm also designs and develops formulas for obesity and pre-diabetes sickness. Its products include Stablor, Bariamed, and Fertimed. It encompass serious game, patient community, and support tools: BariaSpoon and BariaFork. The company was founded by Jérôme Théron and Claude Vincent on October 29, 2010 and is headquartered in Bordeaux, France. | Health Technology |
